Enhancement of DNA Vaccine Potency by Coadministration of a Tumor Antigen Gene and DNA Encoding Serine Protease Inhibitor-6

Tae Woo Kim, Chien Fu Hung, David A K Boyd, Liangmei He, Cheng Tao Lin, Dion Kaiserman, Phillip I. Bird, T. C. Wu

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Serine protease inhibitor 6 (SPI-6), also called Serpinb9, inhibits granzyme B and thus may provide a method for delaying apoptotic cell death in dendritic cells. We have previously enhanced DNA vaccine potency by targeting antigen to MHC antigen presentation pathways, using proteins such as Mycobacterium tuberculosis heat shock protein 70, calreticulin, domain II of Pseudomonas aeruginosa exotoxin A, or the sorting signal of the lysosome-associated membrane protein type 1. In this study, we explored intradermal coadministration of DNA encoding SPI-6 with DNA constructs encoding human papillomavirus type 16 E7 linked to these intracellular targeting molecules for its ability to generate E7-specific CD8+ T-cell immune responses and E7-specific antitumor effects. This combination of strategies resulted in significantly increased E7-specific CD8+ T-cell and CD4+ Th1-cell responses, enhanced tumor treatment ability, and stronger tumor protection when compared with vaccination without SPI-6. Among these targeting strategies tested, mice vaccinated with Sig/E7/lysosome-associated membrane protein type 1 mixed with SPI-6 showed the greatest fold increase in E7-specific CD8+ T cells (∼5-fold). Vaccination with a nonfunctional mutant of SPI-6 did not result in immune enhancement, indicating that enhancement was dependent on the antiapoptotic function of SPI-6. Our results suggest that DNA vaccines combining strategies that enhance MHC class I and II antigen processing with SPI-6 have potential clinical implications for control of viral infection and neoplasia.

Original languageEnglish
Pages (from-to)400-405
Number of pages6
JournalCancer Research
Volume64
Issue number1
DOIs
Publication statusPublished - 2004 Jan 1
Externally publishedYes

Fingerprint

Vaccine Potency
DNA Vaccines
Serine Proteinase Inhibitors
Neoplasm Antigens
DNA
Genes
Lysosome-Associated Membrane Glycoproteins
Antigen Presentation
T-Lymphocytes
Vaccination
Calreticulin
Granzymes
Neoplasms
Histocompatibility Antigens Class I
Th1 Cells
HSP70 Heat-Shock Proteins
Human papillomavirus 16
Histocompatibility Antigens Class II
Virus Diseases
Mycobacterium tuberculosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Enhancement of DNA Vaccine Potency by Coadministration of a Tumor Antigen Gene and DNA Encoding Serine Protease Inhibitor-6. / Kim, Tae Woo; Hung, Chien Fu; Boyd, David A K; He, Liangmei; Lin, Cheng Tao; Kaiserman, Dion; Bird, Phillip I.; Wu, T. C.

In: Cancer Research, Vol. 64, No. 1, 01.01.2004, p. 400-405.

Research output: Contribution to journalArticle

Kim, Tae Woo ; Hung, Chien Fu ; Boyd, David A K ; He, Liangmei ; Lin, Cheng Tao ; Kaiserman, Dion ; Bird, Phillip I. ; Wu, T. C. / Enhancement of DNA Vaccine Potency by Coadministration of a Tumor Antigen Gene and DNA Encoding Serine Protease Inhibitor-6. In: Cancer Research. 2004 ; Vol. 64, No. 1. pp. 400-405.
@article{cab29767056b4367938ddc52a782dfce,
title = "Enhancement of DNA Vaccine Potency by Coadministration of a Tumor Antigen Gene and DNA Encoding Serine Protease Inhibitor-6",
abstract = "Serine protease inhibitor 6 (SPI-6), also called Serpinb9, inhibits granzyme B and thus may provide a method for delaying apoptotic cell death in dendritic cells. We have previously enhanced DNA vaccine potency by targeting antigen to MHC antigen presentation pathways, using proteins such as Mycobacterium tuberculosis heat shock protein 70, calreticulin, domain II of Pseudomonas aeruginosa exotoxin A, or the sorting signal of the lysosome-associated membrane protein type 1. In this study, we explored intradermal coadministration of DNA encoding SPI-6 with DNA constructs encoding human papillomavirus type 16 E7 linked to these intracellular targeting molecules for its ability to generate E7-specific CD8+ T-cell immune responses and E7-specific antitumor effects. This combination of strategies resulted in significantly increased E7-specific CD8+ T-cell and CD4+ Th1-cell responses, enhanced tumor treatment ability, and stronger tumor protection when compared with vaccination without SPI-6. Among these targeting strategies tested, mice vaccinated with Sig/E7/lysosome-associated membrane protein type 1 mixed with SPI-6 showed the greatest fold increase in E7-specific CD8+ T cells (∼5-fold). Vaccination with a nonfunctional mutant of SPI-6 did not result in immune enhancement, indicating that enhancement was dependent on the antiapoptotic function of SPI-6. Our results suggest that DNA vaccines combining strategies that enhance MHC class I and II antigen processing with SPI-6 have potential clinical implications for control of viral infection and neoplasia.",
author = "Kim, {Tae Woo} and Hung, {Chien Fu} and Boyd, {David A K} and Liangmei He and Lin, {Cheng Tao} and Dion Kaiserman and Bird, {Phillip I.} and Wu, {T. C.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-03-1475",
language = "English",
volume = "64",
pages = "400--405",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Enhancement of DNA Vaccine Potency by Coadministration of a Tumor Antigen Gene and DNA Encoding Serine Protease Inhibitor-6

AU - Kim, Tae Woo

AU - Hung, Chien Fu

AU - Boyd, David A K

AU - He, Liangmei

AU - Lin, Cheng Tao

AU - Kaiserman, Dion

AU - Bird, Phillip I.

AU - Wu, T. C.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Serine protease inhibitor 6 (SPI-6), also called Serpinb9, inhibits granzyme B and thus may provide a method for delaying apoptotic cell death in dendritic cells. We have previously enhanced DNA vaccine potency by targeting antigen to MHC antigen presentation pathways, using proteins such as Mycobacterium tuberculosis heat shock protein 70, calreticulin, domain II of Pseudomonas aeruginosa exotoxin A, or the sorting signal of the lysosome-associated membrane protein type 1. In this study, we explored intradermal coadministration of DNA encoding SPI-6 with DNA constructs encoding human papillomavirus type 16 E7 linked to these intracellular targeting molecules for its ability to generate E7-specific CD8+ T-cell immune responses and E7-specific antitumor effects. This combination of strategies resulted in significantly increased E7-specific CD8+ T-cell and CD4+ Th1-cell responses, enhanced tumor treatment ability, and stronger tumor protection when compared with vaccination without SPI-6. Among these targeting strategies tested, mice vaccinated with Sig/E7/lysosome-associated membrane protein type 1 mixed with SPI-6 showed the greatest fold increase in E7-specific CD8+ T cells (∼5-fold). Vaccination with a nonfunctional mutant of SPI-6 did not result in immune enhancement, indicating that enhancement was dependent on the antiapoptotic function of SPI-6. Our results suggest that DNA vaccines combining strategies that enhance MHC class I and II antigen processing with SPI-6 have potential clinical implications for control of viral infection and neoplasia.

AB - Serine protease inhibitor 6 (SPI-6), also called Serpinb9, inhibits granzyme B and thus may provide a method for delaying apoptotic cell death in dendritic cells. We have previously enhanced DNA vaccine potency by targeting antigen to MHC antigen presentation pathways, using proteins such as Mycobacterium tuberculosis heat shock protein 70, calreticulin, domain II of Pseudomonas aeruginosa exotoxin A, or the sorting signal of the lysosome-associated membrane protein type 1. In this study, we explored intradermal coadministration of DNA encoding SPI-6 with DNA constructs encoding human papillomavirus type 16 E7 linked to these intracellular targeting molecules for its ability to generate E7-specific CD8+ T-cell immune responses and E7-specific antitumor effects. This combination of strategies resulted in significantly increased E7-specific CD8+ T-cell and CD4+ Th1-cell responses, enhanced tumor treatment ability, and stronger tumor protection when compared with vaccination without SPI-6. Among these targeting strategies tested, mice vaccinated with Sig/E7/lysosome-associated membrane protein type 1 mixed with SPI-6 showed the greatest fold increase in E7-specific CD8+ T cells (∼5-fold). Vaccination with a nonfunctional mutant of SPI-6 did not result in immune enhancement, indicating that enhancement was dependent on the antiapoptotic function of SPI-6. Our results suggest that DNA vaccines combining strategies that enhance MHC class I and II antigen processing with SPI-6 have potential clinical implications for control of viral infection and neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=1642453782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642453782&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-1475

DO - 10.1158/0008-5472.CAN-03-1475

M3 - Article

VL - 64

SP - 400

EP - 405

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 1

ER -